{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:40:02Z","timestamp":1770961202120,"version":"3.50.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s177127","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T19:13:30Z","timestamp":1534878810000},"page":"1489-1497","source":"Crossref","is-referenced-by-count":14,"title":["Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab"],"prefix":"10.2147","volume":"Volume 14","author":[{"given":"Todd","family":"Wechter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Cline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":true,"given":"Steven","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,8]]},"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=43833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=43833","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T19:13:31Z","timestamp":1534878811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/targeting-p19-as-a-treatment-option-for-psoriasis-an-evidence-based-re-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s177127","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}